Publikace
- Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry2015 | 1. lékařská fakulta
- Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study2015 | 1. lékařská fakulta
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial2015 | Publikace bez příslušnosti k fakultě
- Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines2014 | 1. lékařská fakulta, 2. lékařská fakulta
- Individuální rozdíly farmakokinetiky taxolu u pacientek s rakovinou prsu2007 | 2. lékařská fakulta
- Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data2003 | 2. lékařská fakulta
- Integrative analysis of mRNA and miRNA expression profiles and somatic variants in oxysterol signaling in early-stage luminal breast cancer2023 | 1. lékařská fakulta, 2. lékařská fakulta, Lékařská fakulta v Plzni
- Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study2023 | 1. lékařská fakulta, Lékařská fakulta v Hradci Králové
- The Cost-Effectiveness of Pertuzumab for the Treatment of Metastatic HER2+ Breast Cancer in Czechia: A Semi-Markov Model Using Cost States2023 | Fakulta sociálních věd
- Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer2023 | Publikace bez příslušnosti k fakultě
Loading network view...